V

Viking Therapeutics

VKTX

54.610
USD
-2.38
(-4.18%)
Market Open
Volume
72,703
EPS
0
Div Yield
0
P/E
-67
Market Cap
6,889,307,716
Related Instruments
C
CRBP
-0.500
(-0.84%)
59.160 USD
G
GALT
-0.27000
(-10.80%)
2.23000 USD
G
GNFT
0.10000
(2.41%)
4.25000 USD
I
ICPT
0
(0%)
0.000000 USD
M
MDGL
-6.22
(-2.18%)
278.97 USD
News

Title: Viking Therapeutics

Sector: Healthcare
Industry: Biotechnology
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.